PepGen (PEPG) Other Accumulated Expenses (2021 - 2026)
PepGen (PEPG) posted Other Accumulated Expenses of $2.4 million for Q1 2026, up 1105.94% sequentially from $202000.0 in Q4 2025, and down 78.75% YoY from $11.5 million in Q1 2025.
Analysis
PepGen (PEPG) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
PepGen has reported Other Accumulated Expenses for 6 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Other Accumulated Expenses fell 78.75% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 78.75% YoY) and the FY2025 annual result came in at $202000.0, down 97.07% from the prior year.
- Other Accumulated Expenses improved to $2.4 million in Q1 2026 per PEPG's latest filing, from $202000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $11.5 million in Q1 2025 and troughed at $202000.0 in Q4 2025.
- A 5-year average of $3.2 million and a median of $1.6 million in 2022 frame the typical range for Other Accumulated Expenses.
- The widest YoY moves for Other Accumulated Expenses: up 1103.99% in 2025, down 97.07% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $1.1 million in 2022, then decreased by 18.54% to $918000.0 in 2023, then surged by 651.96% to $6.9 million in 2024, then tumbled by 97.07% to $202000.0 in 2025, then surged by 1105.94% to $2.4 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.4 million, $202000.0, and $476000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 2.44 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 8.90 Mn |
| Mar 31, 2025 | 11.46 Mn |
| Dec 31, 2024 | 6.90 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 9.52 Mn |
| Sep 30, 2023 | 10.27 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 6.96 Mn |
| Dec 31, 2022 | 4.84 Mn |
| Sep 30, 2022 | 3.50 Mn |
| Jun 30, 2022 | 8.50 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 5.34 Mn |